Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Titan Bio-Tech Ltd (524717)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524717 NSE: Chemicals | Small Cap | Titan Bio-Tech Share Price
₹399.95 -3.25 (-0.81%)
As on 13-Oct'26 10:41
Titan Bio-Tech Ltd (524717)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524717 NSE: Chemicals | Small Cap | Titan Bio-Tech Share Price
₹399.95 -3.25 (-0.81%)
As on 13-Oct'26 10:41
Key Metrics
Valuation Multiples
Market Cap
₹1,666 Cr.
Current Price
₹400
52-Week Low / High
₹171 / 556
TTM EPS
₹8.2
TTM Sales
₹219 Cr.
Book Value per Share
₹46.2
P/E Ratio
49.17
Higher than its 5-year historical median
Industry PE
47.6
Price to Book (P/B)
8.72
Higher than its 5-year historical median
Price to Sales (P/S)
7.61
Higher than its 5-year historical median
EV/EBITDA
34.14
Higher than its 5-year historical median
Dividend Yield
0.13%
Profitability Efficiency
Return on Equity (ROE)
16.39%
Outperforms industry median
Return on Capital Employed (ROCE)
22.94%
Outperforms industry median
Return on Assets (ROA)
13.62%
Operating Profit Margin
18.7%
Net Profit Margin
13.31%
Gross Profit Margin
20.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
31.79%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
51.79%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
50.25%
Asset Quality
Promoter Holding
55.78%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹183 Cr.
Equity
₹8.3 Cr.
Face Value
₹2
All Time Low / High
₹0.21 / 555.65
Check Before You Invest
Quality
Very GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Titan Bio-Tech Ltd a good quality company?
Titan Bio-Tech Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Titan Bio-Tech Ltd performance compare with that of its Peers?
Revenue growth of Titan Bio-Tech Ltd vs industry peers?
Titan Bio-Tech Ltd revenue CAGR is 7.71%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Titan Bio-Tech Ltd?
Promoters hold 55.78% of the Titan Bio-Tech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Titan Bio-Tech Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 48.4% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Titan Bio-Tech Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 12.7% | 12.9% | 12.5% | 18.6% | 61.6% | 35.5% | 27.9% | 26.3% | 17.8% | 24.3% | - |
| Value Creation Index ⓘ | -0.1 | -0.1 | -0.1 | 0.3 | 3.4 | 1.5 | 1.0 | 0.9 | 0.3 | 0.7 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 52.5 | 55.5 | 58.2 | 69.5 | 122 | 124 | 144 | 164 | 156 | 206 | 219 |
| Sales YoY Gr. | - | 5.9% | 4.9% | 19.3% | 76.3% | 0.9% | 16.6% | 13.9% | -4.6% | 31.8% | - |
| Adj EPS ⓘ | 0.6 | 0.6 | 0.7 | 1.3 | 6.9 | 5.3 | 5.1 | 5.6 | 4.4 | 6.6 | 7.4 |
| YoY Gr. | - | -6.8% | 18.2% | 106.2% | 417.2% | -24.2% | -3.2% | 10.8% | -21.5% | 50.2% | - |
| BVPS (₹) ⓘ | 6 | 6.3 | 7.7 | 9.2 | 15.9 | 20.9 | 25.7 | 31.1 | 35.1 | 41.4 | 43.6 |
| Adj Net Profit ⓘ | 2.3 | 2.1 | 2.7 | 5.5 | 28.6 | 21.7 | 21 | 23.3 | 18.3 | 27.5 | 31 |
| Cash Flow from Ops. ⓘ | -0 | 1.6 | 6.2 | 6.9 | 17.6 | 22 | 21.2 | 21.2 | 20.1 | 30.4 | - |
| Debt/CF from Ops. ⓘ | -579.6 | 16.3 | 3.5 | 2.6 | 0.5 | 0.3 | 0.3 | 0.3 | 0.1 | 0.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 16.4% | 11% | 12.7% | 31.8% | ||||
| Adj EPS ⓘ | 30.9% | -0.9% | 9.3% | 50.2% | ||||
| BVPSⓘ | 24% | 21% | 17.2% | 17.7% | ||||
| Share Price | 48.5% | 43.8% | 77.3% | 60.6% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 10.2 | 9 | 9.7 | 16 | 55.3 | 28.5 | 21.8 | 19.8 | 13.4 | 17.4 | 17.5 |
| Op. Profit Mgn % ⓘ | 10.5 | 11.9 | 12.9 | 15.7 | 34.2 | 25.3 | 20.5 | 20.9 | 16.3 | 18.7 | 19.4 |
| Net Profit Mgn % ⓘ | 4.3 | 3.8 | 4.6 | 8 | 23.4 | 17.6 | 14.6 | 14.2 | 11.7 | 13.3 | 14 |
| Debt to Equity ⓘ | 1 | 1 | 0.7 | 0.5 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 0 | - |
| Working Cap Days ⓘ | 147 | 175 | 192 | 185 | 150 | 189 | 175 | 168 | 189 | 160 | 76 |
| Cash Conv. Cycle ⓘ | 111 | 140 | 156 | 147 | 102 | 125 | 122 | 122 | 141 | 114 | 51 |
Valuation of Titan Bio-Tech - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 53 | 57 | 65 | 79 | 142 | 124 | 144 | 164 | 156 | 206 |
| Operating Expenses ⓘ + | 47 | 50 | 56 | 66 | 96 | 92 | 114 | 130 | 131 | 168 |
| Operating Profit ⓘ | 5 | 7 | 9 | 13 | 46 | 31 | 30 | 34 | 25 | 39 |
| Operating Profit Margin (%) | 10.2% | 12.2% | 13.7% | 17.0% | 32.5% | 25.3% | 20.5% | 20.9% | 16.3% | 18.7% |
| Other Income ⓘ + | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 2 | 4 | 5 |
| Interest ⓘ | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation ⓘ | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 5 |
| Profit Before Tax ⓘ | 3 | 4 | 6 | 10 | 43 | 29 | 28 | 32 | 24 | 38 |
| Tax ⓘ | 1 | 1 | 2 | 3 | 11 | 7 | 7 | 8 | 6 | 11 |
| Profit After Tax | 2 | 3 | 4 | 8 | 32 | 22 | 21 | 24 | 18 | 27 |
| PAT Margin (%) | 4.1% | 4.7% | 6.0% | 9.9% | 22.3% | 17.6% | 14.6% | 14.4% | 11.7% | 13.3% |
| Adjusted EPS (₹) | 0.6 | 0.7 | 0.9 | 1.7 | 7.3 | 5.3 | 6.0 | 6.0 | 5.2 | 7.2 |
| Dividend Payout Ratio (%) | 26.60% | 22.80% | 0% | 11.70% | 4.10% | 5.70% | 6% | 6.70% | 7.70% | 6.90% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 23 | 24 | 32 | 39 | 69 | 86 | 110 | 133 | 153 | 182 | |
| Debt + | 22 | 25 | 23 | 23 | 13 | 6 | 6 | 7 | 2 | 3 | |
| Minority Interest | 1 | 1 | 2 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 1 | 1 | 2 | 4 | 4 | 4 | 6 | 3 | 8 | 9 | |
| Others Liabilities ⓘ | 4 | 6 | 7 | 9 | 22 | 19 | 20 | 21 | 18 | 29 | |
| Total Liabilities ⓘ | 52 | 58 | 66 | 78 | 111 | 115 | 142 | 165 | 181 | 223 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 13 | 14 | 29 | 31 | 34 | 35 | 36 | 52 | 57 | 62 | |
| CWIP ⓘ | 9 | 13 | 0 | 0 | 0 | 4 | 13 | 3 | 2 | 2 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 4 | 15 | 28 | 33 | 60 | |
| Inventories | 14 | 18 | 21 | 28 | 33 | 35 | 36 | 46 | 51 | 56 | |
| Trade Receivables | 6 | 8 | 9 | 12 | 18 | 16 | 21 | 19 | 19 | 23 | |
| Cash Equivalents | 4 | 1 | 2 | 2 | 5 | 7 | 5 | 3 | 6 | 2 | |
| Others Assets ⓘ | 5 | 4 | 4 | 5 | 21 | 15 | 15 | 15 | 14 | 18 | |
| Total Assets ⓘ | 52 | 58 | 66 | 78 | 111 | 115 | 142 | 165 | 181 | 223 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 0 | 2 | 5 | 6 | 19 | 22 | 21 | 21 | 20 | 30 |
| Cash Flow From Investing Activity ⓘ + | -8 | -6 | -4 | -2 | -5 | -16 | -21 | -20 | -10 | -33 |
| Cash Flow From Financing Activity ⓘ + | 9 | 0 | -0 | -4 | -11 | -4 | -2 | -3 | -8 | -2 |
| Net Cash Flow ⓘ | 1 | -3 | 1 | -0 | 4 | 2 | -2 | -2 | 2 | -4 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 9.8 | 11.27 | 13.84 | 21.97 | 58.74 | 27.98 | 21.44 | 19.45 | 12.74 | 16.39 |
| ROCE (%) | 12.32 | 13.59 | 14.88 | 21.45 | 60.8 | 33.74 | 27.4 | 25.39 | 17 | 22.94 |
| Asset Turnover Ratio | 1.14 | 1.06 | 1.05 | 1.1 | 1.5 | 1.09 | 1.12 | 1.07 | 0.91 | 1.02 |
| PAT to CFO Conversion(x) | 0 | 0.67 | 1.25 | 0.75 | 0.59 | 1 | 1 | 0.88 | 1.11 | 1.11 |
| Working Capital Days | ||||||||||
| Receivable Days | 42.40 | 44.30 | 47.90 | 48.50 | 38.50 | 50.90 | 47.40 | 44.10 | 43.70 | 36.90 |
| Inventory Days | 88.20 | 100.60 | 108.90 | 112.80 | 77.60 | 99.30 | 89.80 | 90.90 | 112.40 | 94.30 |
| Payable Days | 17.30 | 14.30 | 18 | 29.10 | 23.90 | 25 | 25.40 | 21.50 | 27.70 | 30.80 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Titan Bio-Tech Ltd FAQs
The current trading price of Titan Bio-Tech on 13-Oct-2026 10:41 is ₹399.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Oct-2026 the market cap of Titan Bio-Tech stood at ₹1,666 Cr
The latest P/E ratio of Titan Bio-Tech as of 12-Oct-2026 is 54.19.
The latest P/B ratio of Titan Bio-Tech as of 12-Oct-2026 is 9.24.
The 52-week high of Titan Bio-Tech is ₹555.6 and the 52-week low is ₹171.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Titan Bio-Tech is ₹219 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Titan Bio-Tech Ltd is a good quality company.
The key valuation ratios of Titan Bio-Tech Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Titan Bio-Tech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Titan Bio-Tech Ltd
Titan Biotech was established in 1992 with an objective of serving the scientific community and mankind by way of providing good quality of biological products i.e. protein hydrolysis, peptones and their derivatives, extracts, dehydrated microbiological culture media, plant tissue culture media and laboratory chemicals.
All the biological products are basically conducive to the growth of microorganisms and their primary use is in the development and growth of microorganisms in clinical diagnosis, production of vaccines, antibiotics and antisera, antimicrobial susceptibility testing to antibiotics, checking the bacterial contamination in food & water samples in departments of microbiology and relevant fields of science in medical colleges/universities/industries and tissue culture laboratories.
The company has developed more than 1700 Dehydrated Culture Media, Media Bases, and special type of Peptones and Hydrolysates for vaccine production and other uses. Titan uses the basic raw material i.e. Meet, Bile, Liver Blood, Brain, Heart and other parts of the animals in its process procured from the slaughter houses and other vegetable products like soya and casein, etc. converting them into free flowing powder to produce peptones, extracts and hydrolysates which are further used in manufacturing of dehydrated culture media and as raw material in pharmaceutical, health products and other Industries.
Recently it has introduced a wide range of chromomeric / fluorogenic culture media that does not require any further identification tests. This time they are introducing a range of vegetable culture media, which are animal free and possess equivalent growth characteristics to the Culture media that use animal peptones.
Besides these biological products, it also has a range of laboratory chemicals, analytical reagents, stains and indicators and Readymade stain kits. These materials are used in laboratories to carry out various tests and research work.
The company also manufactures wide range of plant growth promotor and its various basic ingredients, hormones, minerals and vitamins premixes as well as amino acid in liquid, powder and granular forms. Itd product Aminofert has become very popular among the users. The basic raw materials of this product are mixtures of amino acids, minerals and vitamins. It gives complete nourishment and helps in growth and productivity.
Product range of the company includes:
Culture Media & Supplements
- Biological Media Bases + TBL Agroses
- Redymade Liquid Media In Sterile Glass Bottle
- Readymade Sterile Liqiud Media in Glass Bottle
- Media Supplements
- Dehydrated Culture Media
- Sterile Media (Gamma Radiations)
Plant Tissue Culture
- Plant Tissue Culture Media
- Plant Growth Improver
Lab Chemicals & Reagents
- Stains and Indicators Solutions
- Readymade Stains Kit
- Readymade Analytical Reagents
- Laboratory Chemicals & Reagents
- Laboratory Disposables
- Lab Chemicals in Bulk
Bulk Products
- Pharma and Healthcare Products
- Agro Products
- Animal Feed Products
- Amino Acids in Bulk Packs
Achievements/ recognition:
- ISO 9001:2000 certified company
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
